19:16 IST
BSE
Annual Report
Kabra Drugs Annual Report
Aanjaay Industries Ltd has submitted its Annual Report for FY 2025-2026 and issued notice for its 37th AGM scheduled for 30th September 2026.
Kabra Drugs Ltd
- Share price
- ₹18.76
- Market cap
- ₹44.48 Cr
- Revenue (annual)
- ₹92.74 Cr
- Net profit (annual)
- ₹4.96 Cr
- P/E (TTM)
- 5.9×Sector 50.4×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements
17:11 IST
BSE
Annual General Meeting
Kabra Drugs Annual General Meeting
Aanjaay Industries Limited announced book closure dates from September 24th to September 30th, 2026, for its Annual General Meeting scheduled for September 30th, 2026.
18:38 IST
BSE
Board Meeting Outcome
Kabra Drugs Board Meeting Outcome
Aanjaay Industries Limited announced the notice for its 37th Annual General Meeting and approved board agenda items, including the appointment of directors and auditors.
18:58 IST
BSE
Financial Results
Kabra Drugs Q1 FY27 Results: Turns Profitable, Net Profit ₹2.1 Cr
Kabra Drugs Ltd reported revenue from operations of ₹46.2 Cr (+541.7% YoY) and net profit of ₹2.1 Cr for Q1 FY27.
- Key figure
- Net profit ₹2.1 Cr
19:03 IST
BSE
Financial Results
Kabra Drugs Q4 FY26 Results: Net Profit ₹1.1 Cr, Up 175.0% YoY
Kabra Drugs Ltd reported revenue from operations of ₹35.4 Cr and net profit of ₹1.1 Cr (+175.0% YoY) for Q4 FY26.
- Key figure
- Net profit ₹1.1 Cr · +175.0% YoY